U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07190391) titled 'Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis' on Sept. 17.
Brief Summary: This study aims to evaluate the efficacy and safety of Apremilast tablets in patients with psoriasis over 32 weeks, through a multicenter, single-arm, open-label, phase 4 clinical trial.
Study Start Date: Sept. 30
Study Type: OBSERVATIONAL
Condition:
Psoriasis
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Daewoong Pharmaceutical Co. LTD.
Published by HT Digital Content Services with permission from Health Daily Digest....